There are currently 17 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. The states with the highest number of trials for Primary Sclerosing Cholangitis participants are California, Virginia, Texas and Florida.
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
NCT03175471
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastogr... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Register for Updates
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
NCT03178630
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection o... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
NCT04685200
Recruiting
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease. Researchers want to learn more about this disease. Objective: To understand the biological causes of primary sclerosing cholangitis. Eligibility: Adults age 18 and older who have primary sclerosing cholangitis. Design: Participants will be screened with a medical history, physical exam, a... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Sclerosing Cholangitis
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/19/2024
Locations: Southern California Research Center, Coronado, California +89 locations
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
NCT06197308
Recruiting
This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
12/10/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Primary Sclerosing Cholangitis
Register for Updates
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
NCT05750498
Recruiting
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. Pediatric Autoimmune Hepatitis (AIH) and Primary Scleros... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Stanford University, Palo Alto, California +7 locations
Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
NCT05295680
Recruiting
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC). Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care. To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely:... Read More
Gender:
ALL
Ages:
Between 14 years and 75 years
Trial Updated:
11/24/2024
Locations: Stanford Clinic, Redwood City, California +1 locations
Conditions: Primary Sclerosing Cholangitis
Register for Updates
A Study of SIPLIZUMAB in AILD and LT Patients
NCT06455280
Recruiting
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York
Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Register for Updates
Primary Sclerosing Cholangitis in Children
NCT04181138
Recruiting
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver. The purposes of this study are to: Collect medical and other data to learn more about PSC, how it progresses, and... Read More
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
06/04/2024
Locations: Children's Hospital of Los Angeles, Los Angeles, California +11 locations
Conditions: Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Register for Updates
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
NCT03561584
Recruiting
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.
Gender:
All
Ages:
Between 15 years and 80 years
Trial Updated:
04/19/2024
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Detoxification of the Liver In PSC (Dolphin)
NCT05835505
Recruiting
This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participa... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/19/2024
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
NCT05912387
Recruiting
PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/19/2024
Locations: Stanford University, Stanford, California
Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Register for Updates